Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed) | RFA CA 21 003

Opportunity Information: Apply for RFA CA 21 003

The Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed) opportunity, listed as RFA-CA-21-003, is a National Institutes of Health (NIH) funding announcement under the National Cancer Institute (NCI) that supports exploratory, early-stage research projects aimed at creating brand-new technology capabilities for cancer research. It sits within NCI's broader Innovative Molecular Analysis Technologies (IMAT) Program, which is specifically built to push forward next-generation tools that help scientists interrogate cancer in ways that are not currently possible or are meaningfully limited by today’s methods.

The central goal of this FOA is technology development rather than incremental biological discovery. Applicants are expected to propose highly innovative molecular or cellular analysis technologies that introduce genuinely new ways to target, probe, measure, or otherwise assess key molecular and cellular features of cancer biology. In practical terms, this means the emphasis is on tools and methods that can open up new dimensions of measurement, improve sensitivity or specificity, enable new kinds of spatial or temporal resolution, increase throughput, reduce sample requirements, or make previously inaccessible cancer-relevant measurements feasible in real-world research or clinical settings. Projects are meant to be exploratory in nature, consistent with the R21 mechanism, and focused on demonstrating feasibility and potential impact rather than delivering a fully mature, widely deployed platform.

While the technologies may be broadly applicable across many cancer types or research contexts, the work must be clearly centered on improving molecular and/or cellular characterization of cancer biology. The FOA highlights that well-aligned proposals should have a strong likelihood of accelerating or enhancing cancer research and downstream applications across areas such as fundamental cancer biology, early detection and screening, clinical diagnosis, treatment and treatment selection, cancer control, epidemiology, and efforts that address cancer health disparities. In other words, the technology should not just be technically clever; it should plausibly change what researchers and clinicians can measure or understand about cancer, and it should be positioned to improve the pace, quality, or reach of cancer-related research and, ultimately, patient-impacting pipelines.

This particular announcement is explicitly "Clinical Trial Not Allowed," meaning applicants should not propose studies that meet NIH’s definition of a clinical trial. The intent is to support preclinical or non-trial technology development and validation activities that lay the groundwork for later translational studies, rather than funding interventional clinical research within this award.

From an administrative standpoint, the opportunity is a discretionary grant in the Education and Health activity category and is associated with CFDA number 93.394. The listed award ceiling is $200,000, indicating a relatively modest budget consistent with early-stage, proof-of-concept technology development. The original closing date shown is September 29, 2021, and the FOA creation date is November 20, 2020, which is important for applicants assessing whether this specific solicitation is still active versus serving as a reference point for future or reissued IMAT-related opportunities.

Eligibility is broad and includes many types of U.S.-based applicants: state, county, city/township, and special district governments; public and state-controlled and private institutions of higher education; independent school districts; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses) as well as small businesses; and other entities. The FOA also explicitly calls out additional eligible applicant categories that are often emphasized for inclusive participation, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Indian/Native American Tribal Governments that are not federally recognized, U.S. territories or possessions, regional organizations, eligible federal agencies, faith-based or community-based organizations, and non-U.S. entities (foreign organizations).

Overall, this grant opportunity is best understood as a targeted catalyst for bold, technically novel measurement and analysis approaches that can reshape molecular and cellular cancer research. Competitive projects are those that convincingly argue that the proposed technology provides a new capability (not just an optimization), explain why that capability matters for important cancer research or clinical questions, and outline a realistic early-stage development plan that demonstrates feasibility and future utility without drifting into conducting a clinical trial.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on 2020-11-20.
• Applicants must submit their applications by 2021-09-29. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 21 003

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: